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doi:10.1016/j.jtcvs.2006.03.046bjective: We have developed a new technique that uses the ratios of select gene
xpression levels to translate complex genomic data into simple clinically relevant
ests for the diagnosis and prognosis of cancer. We determined whether select gene
air ratio combinations can be used to detect and diagnose lung cancer with high
ccuracy and sensitivity.
ethods: We used gene expression profiling data to train a ratio-based predictor
odel to discriminate among a set of samples (n  145 total) composed of normal
ung, small cell lung cancer, adenocarcinoma, squamous cell carcinoma, and pul-
onary carcinoid (the training set). We then examined the optimal test in an
ndependent set of samples (the test set, n  122). Finally, we used one aspect of
he test to determine whether the gene ratio technique was capable of detecting
ancer in specimens from fine-needle aspirations performed ex vivo with normal
ung (n  14) and suspected tumor nodules (n  15) acquired at our institution.
esults: We found that a ratio-based test with 23 genes could be used to classify
raining set samples with 90% accuracy. This same test was similarly accurate
88%) when applied to the test set of samples. We also found that this test was 87%
nd 100% accurate at detecting cancer in normal and tumorous fine-needle aspira-
ion specimens, respectively.
onclusion: The gene expression ratio diagnostic technique is likely to aid in the
ifferential diagnosis of solitary lung nodules in patients with suspected cancer and
ay also prove useful in developing lung cancer screening strategies that incorpo-
ate analysis of fine-needle aspiration specimens.
ung cancer is one of the most common cancers in the Western world and the
number one cause of cancer deaths for both men and women in the United
States. As many as 80% of patients with lung cancer have non–small cell
ung cancer, a histologic category of primary lung cancer that includes adenocar-
inoma, squamous cell carcinoma (SCC) and large cell carcinoma. Most of the
emainder have small cell lung cancer (SCLC). Other types of primary lung
alignancies include pulmonary carcinoid (1% of all primary lung malignancie1,2
Most patients with lung cancer are seen with advanced disease not amenable to
urgical therapy. However, screening with spiral computed tomography (CT) for
ung cancer is a technique rapidly gaining popularity in the United States, with the
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EToal of identifying lung cancer at early stages, when it is far
ore likely to be curable with surgery.3 Initial studies o
his new screening technology have demonstrated a high
ncidence of nonmalignant nodules in the lungs of former
mokers. The preliminary recommendations are to measure
adiographic volume change of all subcentimeter nodules at
-month intervals and to obtain biopsy samples of any
rowing nodule. Biopsy to obtain definitive diagnosis of
ny noncalcified nodule greater than 1 cm is also advis3-6
iopsies can be accomplished surgically with video-assisted
horacoscopic surgery or by transthoracic fine-needle aspi-
ation (FNA).
Percutaneous CT-guided transthoracic FNA of lung nod-
les is a safe and well-accepted cytopathologic diagnostic
echnique that has been applied to lesions as small as 5 mm.
here are very few false-positive cytologic diagnoses, but the
alse-negative rate has been reported to approach 30%.7 The
bility of a cytologist to make a correct diagnosis depends
n the quality of cells obtained and the preservation of
issue architecture. Cytologic diagnosis by FNA is also
indered by the frequent inability of the cytologist to deter-
ine the type of cancer found in the pulmonary nodule and
o differentiate metastatic cancer to the lung from primary
ung cancer.8 As a consequence, the clinical diagnos
trategy in the management of many newly discovered
ulmonary nodules is to surgically remove those nodules for
hich a definitive benign histologic typing has not been
btained or to monitor all subcentimeter nodules with in-
erval CT scans and remove them surgically if they g9
Gene expression profiling with microarrays and complex
ioinformatics tools has been used successfully to diagnose
ancer and predict disease-related outcome for multiple
eoplasms, including lung cancer.10-12 Unfortunately, these
odels are difficult to assess clinically because they rely on
he measurement of expression levels of relatively large
umbers of genes with costly data-acquisition platforms and
ophisticated algorithms and software. We recently de-
cribed a method for translating gene expression profiling
ata into clinically relevant tests with ratios of gene expres-
ion for multiple cancers.13-17 Here we report the discove
f differentially expressed genes among normal lung and
Abbreviations and Acronyms
CI  confidence interval
CT  computed tomography
FNA  fine-needle aspiration
RT-PCR reverse transcriptase–polymerase chain
reaction
SCC  squamous cell carcinoma
SCLC  small cell lung cancerultiple types of lung cancer. We then used these genes in 8
22 The Journal of Thoracic and Cardiovascular Surgery ● Septehe development of a gene ratio method for the differential
iagnosis of lung cancer or pulmonary nodule. Finally, we
rovide evidence suggesting that this technique may com-
lement ongoing lung cancer screening strategies through
he analysis of FNA samples.
ethods
olid Tumor and FNA Samples
olid samples and ex vivo FNA specimens were collected from 15
onsecutive patients undergoing lung resection for cancer at
righam and Women’s Hospital. As soon as the specimen was
urgically removed from the patient, it was taken to the frozen-
ection room, where, under the supervision of the pathologist,
NA was obtained from the palpable nodule through the surround-
ng pulmonary parenchyma by means of equipment and protocols
dentical to those currently used by cytopathologists at our insti-
ution (3-mL syringe and 22-gauge needle 1.5 inches long). Aspi-
ated FNA material was immediately placed in RNA extraction
uffer (Trizol reagent; Invitrogen Corporation, Carlsbad, Calif) for
rocessing. The diagnostic criterion standard was obtained after
athologic analysis of the solid tumor sample. Studies that used
uman tissues were approved by and conducted in accordance with
he policies of the Institutional Review Board at Brigham and
omen’s Hospital.
ene Expression Profiling Data
icroarray data for normal and tumorous tissues were obtained
rom two sources. Gene expression data for the training set of
amples (n  145 total) were obtained with Affymetrix high-
ensity oligonucleotide microarrays (U95A chip; Affymetrix,
anta Clara, Calif) with probe sets representing approximately
2,000 genes and consisting of normal lung (n  13) and the
ollowing primary tumors: SCLC (n  7), lung adenocarcinoma
n  89), lung SCC (n  24), and pulmonary carcinoid (n  12).18
ene expression data for all additional primary and metastatic
umor samples (the test set) were acquired from a single source
ith the same Affymetrix U95A microarray.19 Primary tumors o
he test set consisted of lung SCC (n  13) and the following
denocarcinomas: prostate (n  24), colon (n  20), breast (n 
5), gastroesophageal (n  12), pancreatic (n  6), and lung (n 
3). Metastatic tumors in the test set (n 9) included those arising
rom breast, colon, prostate, lung, and kidney tumors.
ata and Statistical Analysis
o train an expression ratio-based predictor model, we used an
pproach similar to that in previous published studies.13-17 We
erformed five separate analyses to determine differences in gene
xpression patterns between two groups composed of multiple
ombinations of tissues chosen from the 145 training set samples.
n each of the five training subsets, one group was composed of all
vailable samples of a single tissue type, whereas the other group
onsisted of a random sampling of all remaining tissue types, with
qual representation according to the remaining tissue type with
he smallest number of samples. For example, the lung adenocar-
inoma training subset (n  117 total) examined differences in
ene expression between two groups, lung adenocarcinoma (n 
9) and not lung adenocarcinoma (n 28, consisting of 7 samples
mber 2006
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ETach of the other four tissue types according to the total number of
CLC tissues). This process was repeated sequentially for the
emaining training subsets: SCLC (n 55 total), normal lung (n
1 total), lung SCC (n  72 total), and pulmonary carcinoid (n 
4 total). This experimental design resulted in five training sets
ABLE 1. Lung nodule diagnostic genes
enBank accession no. P value Ratio*
No
38486 6.7  1016 179 Mi
I312905 1.6  1014 439 ES
91211 7.8  1014 15 Ad
88587 2.5  1011 14 Fic
04111 4.4  107 0.35 v-j
19185 2.7  105 0.34 Pe
69043 9.5  105 0.46 Sig
Lu
B000712 2.4  109 94 Cla
F001294 4.0  109 3.6 Tu
05581 1.7  107 4.1 Mu
18728 3.0  107 5.4 Ca
78388 7.3  1010 0.31 Ne
25756 1.2  107 0.03 Se
15979 1.4  107 0.02 De
07335 2.1  107 0.22 Se
Lu
21389 8.2  1011 30 Ke
16961 1.8  108 23 Tu
42611‡ 3.9  108 18 Ke
97105 8.7  107 0.37 Dih
F004563 1.7  105 0.48 Sy
F042792 8.0  105 0.32 Ca
43203 1.8  104 0.26 Th
Sm
82345 1.6  108 16 Th
A203476 5.6  108 9 Pit
73379 1.1  107 17 Ub
00762 6.6  107 11 Pr
25080 8.4  105 0.28 ras
05409 8.0  104 0.2 Ald
59798 .002 0.24 Cy
04366 .008 0.25 Ca
Pu
18983 1.6  1010 11 Pr
B014558 7.8  1010 102 Cr
96750 4.6  107 350 ras
00064 5.8  107 118 Ch
A203487 5.4  108 0.03 CD
A631972 1.1  107 0.01 Na
67325 1.2  107 0.15 Int
62744 3.5  107 0.01 Ma
ight diagnostic genes for each tissue type were chosen for further study
nd four genes were expressed at relatively higher levels in an equal num
issue type/average expression level in all other tissue types combined. †
he filtering criteria. ‡This gene was represented by multiple probe sets oith unique sample numbers (and membership) and was used to i
The Journal of Thoraciciscover optimal discriminating genes in an unbiased fashion
hile ensuring equal representation among multiple tissue types.
The selection of predictor genes for use in expression ratio-
ased diagnosis was performed essentially as described,15,16 with
inor modifications. With a 2-sided Student (parametric) t test, we
Description (LocusLink ID)
lung†
brillar-associated protein 4 (MFAP4)
ed glycosylation end product-specific receptor (AGER)
(FCN3)
vian sarcoma virus 17 oncogene homolog (JUN)
edoxin 2 (PRDX2)
equence receptor, delta (SSR4)
enocarcinoma
4 (CLDN4)
suppressing subtransferable candidate 3 (TSSC3)
1, transmembrane (MUC1)
embryonic antigen-related cell adhesion molecule 6 (CEACAM6)
al protein (NP25)
granin II (SCG2)
ke homolog, Drosophila (DLK1)
ermining region Y-box 2 (SOX2)
uamous cell carcinoma
5 (KRT5)
protein 63 kd with strong homology to p53 (TP63)
6A (KRT6A)
pyrimidinase-like 2 (DPYSL2)
n binding protein 1 (STXBP1)
channel, voltage-dependent (CACNA2D2)
transcription factor 1 (TITF1)
ell lung cancer
in, beta (TMSNB)
y tumor transforming 1 (PTTG1)
n-conjugating enzyme E2C (UBE2C)
ome subunit, alpha type, 3 (PSMA3)
olog gene family, member A (ARHA)
e dehydrogenase 2 (ALDH2)
1 (CCND1)
1 (CAPN1)
ary carcinoid
tyrosine phosphatase, receptor type, N (PTPRN)
hrome 2, photolyase-like (CRY2)
olog gene family, member I (ARHI)
granin B (CHGB)
ntigen (CD68)
killer cell transcript 4 (NK4)
on, alpha-inducible protein 27 (IFI27)
istocompatibility complex, class II, DM alpha (HLA-DMA)
genes were expressed at relatively higher levels in a single tissue type,
of all other tissue types combined. *Average expression level in a single
hree genes (not four) were overexpressed in all abnormal tissues and fit
expression profiling platform of the training set (see Methods section).rmal
crofi
T
vanc
olin
un A
roxir
nal s
ng ad
udin
mor
cin
rcino
uron
creto
lta-li
x-det
ng sq
ratin
mor
ratin
ydro
ntaxi
lcium
yroid
all c
ymos
uitar
iquiti
oteas
Hom
ehyd
clin D
lpain
lmon
otein
yptoc
Hom
romo
68 a
tural
erfer
jor h
. Four
ber
Only tdentified statistically significant (see Table 1 for exact P values)
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ETenes with inversely correlated average expression levels between
oth groups in each of the five training subsets. We then filtered
he resulting gene lists to find those genes with at least a 2-fold
ifference in average expression levels between groups. To mini-
ize the effects of background noise, the list of distinguishing
enes was additionally refined by requiring that the mean expres-
ion level (Affymetrix average difference) be greater than 500 in at
east one of the two groups, similar to previous studies.15,16 A
arge number of genes were found to fit the filtering criteria in each
f the training subsets. To further reduce the number of genes, we
andomly chose for additional study a total of 8 genes from the
mong the most statistically significant differentially expressed
enes in each training subset. Four of these genes were expressed
t relatively higher levels in a single tissue type, and 4 were
xpressed at relatively higher levels in the remaining tissue types
ombined. There was a single exception: in the normal lung
raining subset, only 3 genes were expressed at relatively higher
evels in all abnormal tissues. In one training subset (lung SCC),
here was a single case of duplication among the genes chosen for
urther analysis, considering that (1) we randomly chose additional
enes for study, (2) we initially identified genes strictly on the
asis of their unique Affymetrix probe set identifiers (and not gene
ame), and (3) the same gene can be represented by multiple
ffymetrix probe sets.
All possible nonredundant gene pair expression ratios were
eparately calculated for each sample in all five training subsets by
lacing single genes overexpressed in each tissue type in the
umerator and single genes overexpressed in the combination of
ll other tissues in the denominator. All negative Affymetrix
verage difference values (undetectable) were arbitrarily assigned
n expression level of 1 to facilitate meaningful comparisons. The
dentity of samples used to generate the gene lists was then
redicted in a binary manner with ratio values and a threshold
qual to 1. For example, in the lung adenocarcinoma analysis,
ndividual samples with ratio values greater than 1 and less than 1
ere predicted to be lung adenocarcinoma and not lung adenocar-
inoma, respectively. A final diagnostic call was made from the
alue of the geometric mean of the three most accurately predic-
ive individual ratios with the same criteria. Use of the geometric
ean value for multiple ratios has the effect of giving equal
eights to ratio changes of identical magnitude but opposite di-
ection on the log scale. Finally, all five tissue-specific 3-ratio tests
ere used to comprehensively analyze the 145 training set sam-
les. We hypothesized that the identity of any given sample would
e the tissue with the greatest geometric mean. No-calls were made
onservatively when no tissue-specific geometric mean was
reater than 1. In these cases, a diagnosis was attempted with a
 a j ority rules voting approach15 by considering only the directio
and not the magnitude) of all 15 individual tissue ratios relative to the
hreshold value. The test set of samples was analyzed in exactly
he same manner with identical Affymetrix probe set identifiers.
he classification accuracy of the model in a subset of the test set
nd in FNA samples was assessed with an exact 1-sample binomial
est. The P values are reported under the null hypothesis of
ifferential diagnosis randomly assigned with equal probability of
.5 based on 1-sided tests to reject lower levels of accuracy. The
5% confidence interval (CI) for proportions is based on the exact
inomial distribution. All calculations and statistical comparisons l
24 The Journal of Thoracic and Cardiovascular Surgery ● Septeere generated with S-PLUS20, except the exact binomial proce-
ures, which were computed with Stata 7 (Stata Corporation,
ollege Station, Tex).
eal-time Quantitative Reverse
ranscriptase–Polymerase Chain Reaction
eal-time quantitative reverse transcriptase–polymerase chain re-
ction (RT-PCR) was performed as described with 2 g of total
NA.16 Primer sequences (synthesized by Invitrogen) used 
T-PCR were as follows (forward and reverse, respectively):
FAP4 (5=-ACTTCTCCATCTCCCCGAAC-3= and 5=-TGGTA-
GACAGGGAGTCACC-3=), PRDX2 (5=-AGACAATGGAATG-
CAGCTT-3= and 5=-TGCCCAGAAGTGGCATTAGT-3=), AGER
5=-TCCACTGGATGAAGGATGGT-3= and 5=-CAGCTGTAG-
TTCCCTGGTC-3=) and SSR4 (5=-GGAGCAGGATGCGTAT-
GGA-3= and 5=-TCTGACTGCACAGATTCTTGG-3=).
esults
dentification of Predictor Genes and Generation of a
odel for the Differential Diagnosis of Lung Nodules
ith Gene Expression Ratios
e discovered a total of 39 predictor genes that fit the filtering
riteria and were chosen for further analysis (Table 1). W
alculated and assessed for classification accuracy a total of
6 possible individual gene pair ratios for all training sub-
ets except normal lung. We calculated 12 possible gene
air ratios for this subset, since only three genes (not four)
ere expressed at relatively higher levels in all abnormal
issues. We have previously shown that optimal classifica-
ion accuracy with expression ratio-based methods can be
chieved in most circumstances by combining the expres-
ion data from the three most accurate individual gene pair
atios.15,16 We therefore obtained a combined score (g-
etric mean, see Methods section) for each of the training
ubset samples with the three most accurate ratios from each
raining subset. We found that we could identify these
amples with very high accuracy (Table 2).
Finally, to systematically and comprehensively analyze
he entire cohort of training set samples in parallel, we
alculated all 15 ratios (from Table 2) for every trainin
ample (n 145 total) and predicted a tissue type according
o the criteria stated in the Methods section. Not surpris-
ngly, we discovered that expression ratio diagnosis with
hese 23 genes was highly accurate: 90% (130/145, 95% CI
4%-94%, P  106) of the samples were correctly pre-
icted with 5 errors and 10 no-calls. The no-calls included
denocarcinoma (n  6), pulmonary carcinoid (n  1), and
CC (n  3). Importantly, no tumors were called normal.
f the 13 initial no-calls, 3 were resolved on further analysis
as described in the Methods section) and 10 samples re-
ained without definitive diagnosis. The 10 final no-call
amples had very low, or more frequently undetectable,
xpression levels for multiple genes used in the analysis,
hich likely reflects microarray defects or artifacts re-ated to sample preparation. Interestingly, we found that
mber 2006
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ET2% of samples (17/145) had multiple (n  2 in all cases)
ombined scores greater than 1. Of these, 88% (15/17)
ere called correctly, with an average 7-fold difference
etween both combined scores (range 1.3-46.8), with the
arger of the two combined scores used to assign a
iagnosis.
erification of Expression Level Ratios As a
iagnostic Tool
ext we tested the ability of these five highly accurate
xpression ratio combinations to diagnose cancer in a sep-
rate cohort of 113 primary tumors and 9 metastatic tumors
the test set) for which expression profiling data were avail-
ble.19 A total of 26 samples (n  13 each of primary lun
denocarcinoma and lung SCC) were directly relevant to the
alidation of the model developed here because they were
btained from primary lung lesions. The remaining tumors
ere adenocarcinomas originating from tissues other than
ung or represented metastatic disease, and we used these
amples to test multiple hypotheses. We first hypothesized
hat adenocarcinomas of diverse origin are more similar to
ne another than to any of the other four tissue types
xamined in this study with respect to global gene expres-
ion patterns, specifically the 23 genes used in the expres-
ion ratio diagnostic model. We also hypothesized that the
iagnostic model developed here would be equally applica-
le in analyzing metastatic tumors. To perform this analysis,
e used the expression values for all 23 diagnostic genes to
alculate the five most accurate 3-ratio combinations and
redicted the identity of all 122 samples with exactly the
ame criteria as before. In this analysis, the classification
ccuracy for all adenocarcinomas was evaluated without
espect to tissue type of origin. The results for the classifi-
ation of primary tumors (n  113) are presented in Table 
ABLE 2. Diagnostic accuracy of 3-ratio combinations in
raining subsets
-Ratio test* Accuracy
ormal lung: MFAP4\PRDX2,
AGER\PRDX2, AGER\SSR4
100% (41/41)
ung adenocarcinoma: CLDN4\SOX2,
CLDN4\NP25, TSSC3\SOX2
89% (104/117)
ung SCC: KRT5\CACNA2D2,
KRT6A\TITF1, KRT6A\STXBP1
90% (65/72)
CLC: PTTG1\CCND1,
PSMA3\ALDH2, TMSNB\ALDH2
100% (55/55)
ulmonary carcinoid: PTPRN\NK4,
CRY2\CD68, CRY2\HLA-DMA
98% (63/64)
he three most accurate individual ratios identified in each training subset
ere combined and used to obtain a diagnostic call for samples contained
ithin each subset. *Genes are represented by LocusLink symbols found
n Table 1.verall, our model was 88% (107/122, 95% CI 81%-93%, t
The Journal of Thoracic 106) accurate in identifying the tumor type of test set
amples and was 88% (100/113, 95% CI 81%-94%, P 
06) and 78% (7/9, 95% CI 40%-97%, P  .090) accu-
ate within the subsets of primary and metastatic tumors,
espectively. Specifically, we found that we could accu-
ately (26/28 or 93%, 95% CI 76%-99%) and signifi-
antly (P  2  106) predict the identity of primary
ung tumors and successfully diagnose both metastatic
ung tumors.
nalysis of Ex Vivo FNA Samples
here is ample evidence that material obtained from FNA is
ufficient for both microarray and RT-PCR analysis.12,21-24
e therefore performed a study to test directly the potential
f gene ratios to accurately detect cancer in FNA-derived
amples. We used simulated ex vivo FNAs in these initial
tudies to determine whether sample-acquisition procedures
ntroduced variability and possibly affected the outcome of
he test. Pathologic analysis of a portion of the solid spec-
men classified these 15 nodules as non–small cell lung
ancer (n  6), SCC (n  3), SCLC (n  1), pulmonary
arcinoid (n  2), bronchoalveolar carcinoma (n  1),
denocarcinoma (n  1), and benign fibrosis (n  1). With
uantitative RT-PCR, we obtained gene expression data for
he four genes comprising the normal lung versus lung
umor test (from Table 2) from each FNA specimen. 
e calculated all three ratios in this test and determined
hether each individual sample was normal lung or lung
umor, according to the criteria detailed here. We found that
atio-based testing could accurately identify FNA samples
P  106) from nonmalignant specimens (87% specificity,
3/15, 95% CI 60%-98%) and tumor specimens (100%
ensitivity, 14/14, (95% CI 81%-100%). Importantly, nei-
ABLE 3. Distribution of class predictions for test
et samples
ctual identity of
nknown sample
Predicted class
LADCA LSCC SCLC PC NL No call
ADCA 12 1
SCC 1 12
R 24
O 19 1
R 20 1 1 3
A 9 1 1 1
A 4 1 1
he value in each box is the number of primary tumors from the test set
n  113) predicted with a given identity from the expression ratio-based
odel developed in the training set of samples. LADCA, Lung adenocar-
inoma; LSCC, lung SCC; PC, pulmonary carcinoid; NL, normal lung; PR,
rostate adenocarcinomas; CO, colon adenocarcinomas; BR, breast ade-
ocarcinomas; GA, gastroesophageal adenocarcinomas; PA, pancreatic
denocarcinomas.her of the two misclassified samples were tumor tissues
and Cardiovascular Surgery ● Volume 132, Number 3 625
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6
ETfalse-negative results). Interestingly, one preoperatively
uspected tumor FNA sample was predicted to be nonma-
ignant (normal lung) by the ratio-based cancer detection
est. On final pathologic review, it was determined that this
odule was in fact a fibrotic mass and not a tumor.
iscussion
n this report, we applied the gene ratio technique13-17 to the
etection and diagnosis of lung cancer with a combined
pproach consisting of multiple data-acquisition platforms
nd sample sources. The primary strength of this technique
s that quantitative RT-PCR can be used to validate the
odel in additional samples and without further refer-
nce to training samples with data acquired on the same
latform. In this way, it becomes possible for other
linical investigators without access to complex bioinfor-
atics tools to reproduce initial findings in large numbers
f samples worldwide. Here for the first time we extend
his technique to the classification of more than two
issue types and provide evidence strongly suggesting
hat this technique is equally useful in the analysis of
NA-derived material.
Strategies to reduce mortality from lung cancer include
he development and implementation of an effective screen-
ng system such as spiral CT for at-risk populations. Even as
his technique is being studied, it is also being rapidly
mplemented by physicians, in many cases on demand by
atients willing to bear the cost. Spiral CT of the chest can
e excessively sensitive, and it is generally estimated that
nly 10% of nodules detected in the lungs of smokers are
ctually cancerous.3,4,25 FNA of newly discovered pulm-
ary nodules is an attractive technique, but unfortunately is
urrently limited by the size of the nodule and the accuracy
f cytopathologic examination, specifically in distinguish-
ng between false- and true-negative results, which may
ccount for up to a third of all biopsy specimens.7 The major
roblem is that a negative cytologic result is simply a
egative result in the majority of cases. This is often due to
nadequate sampling or lack of sufficient cytologic features
o call the sample a tumor.8 The gene ratio method c
otentially address several of these clinical insufficiencies.
or example, it could add a genomic component to the
iagnosis that requires only the extraction of very small
uantities of tumor RNA (tissue), thereby facilitating the
cquisition of samples that would otherwise not demon-
trate cytologically diagnostic tumor cells. Also, in the
oncept of gene ratio-based analysis, a diagnosis of nonma-
ignant is actually a positive diagnosis of benign tissue and
ot necessarily just a negative result. In our studies, both of
he misclassified FNA samples proved to be normal lung, a
isappointing finding considering that the virtue of FNA
ytopathologic examination is its low false-positive rate.
ince samples of normal lung tissue were harvested from a
26 The Journal of Thoracic and Cardiovascular Surgery ● Septehe same patient in an area proximal to the suspected tumor,
he margin could have been contaminated with histologi-
ally undetectable tumor cells, or transformed epithelial
ells that have not yet formed a tumor. Alternatively, the
isclassification could have resulted from inherent biologic
ariability reflected in gene expression. Unfortunately, as in
imilar pilot studies,12 sufficient material was not availab
o conduct cytologic analyses, which might have addressed
ome of these possibilities. To examine all these hypotheses
ystematically, we are conducting additional studies to re-
ne the list of discriminating genes and prospectively ob-
aining consent and collecting FNA material linked to cy-
ologic findings for use in follow-up studies.
Our experiments used an ideal scenario (an ex vivo
NA) to test the ability of multiple distinguishing genes to
lassify normal and malignant tissues accurately in the
ontext of a gene expression ratio-based model. Even
hough the syringe, needle gauge, and biopsy technique
ere all similar to those typically used by cytopathologists
t our institution, before implementation this technique will
equire rigorous testing to take into account additional clin-
cal parameters, such as patient movement. Considering that
he ex vivo FNA specimen was acquired through the sur-
ounding pulmonary parenchyma and was still accurate at
etecting tumor, we believe that the genes as reported will
e suitable for use in actual FNA specimens. Recent work
y other investigators has demonstrated the general feasi-
ility of using transthoracic CT–guided FNA biopsy to
btain material with RNA suitable for even stringent
pplications, such as gene expression profiling with
icroarrays.12
The genes used in this study have also been partially
alidated by another group of investigators who used a
ingle gene pair ratio (RAGE/cyclin-B2) to detect lung
ancer.26 We independently found that RAGE (also known
s AGER) is overexpressed in normal lung relative to tumor,
nd thus it is part of our normal lung test (Table 2). W
ound that cyclin-B2 was statistically significantly (P 
013) downregulated in normal lung relative to tumors.
owever, cyclin-B2 was not among our final list of
iscriminating genes, probably because of fundamental
ifferences in experimental designs, because we exam-
ned a broader number of tumor types and used multiple
enes and ratios.
In conclusion, we have produced evidence strongly sug-
esting that FNA specimens are suitable for gene ratio-
ased detection and diagnosis of lung cancer, and we are
ow conducting prospective studies to validate these initial
roof-of-principle experiments. We ultimately view this
echnique as an adjunct and extension to current cytopatho-
ogic techniques in the evaluation of suspect lung nodules.
hereas cytopathologists require the preservation of tissue
rchitecture and intact cells for definitive diagnosis, our
mber 2006
p
m
o  of
F
p
a
a
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
Gordon et al Evolving Technology
ETroposed analysis only requires intact tumor RNA. Further-
ore, other gene ratio-based tests, such as for the prognosis
f lung cancer,14 may also be applicable to the analysis
NA specimens to aid in tailoring the best therapy for the
atient in whom cancer is detected and diagnosed. This
pproach may ultimately allow clinicians to tailor the ther-
py of individual cancer patients.20
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